Head and Neck Squamous Cell Carcinomas (HNSCC) – Cell and Gene Therapies 15-Market Assessment and Sales Forecast to 2031
Powered by ![]()
All the vital news, analysis, and commentary curated by our industry experts.
Head and Neck Squamous Cell Carcinomas (HNSCC) Market Report Overview
The total head and neck squamous cell carcinomas market value for the 15M, which includes both cell and gene therapies and established/traditional HNSCC therapies was $1.9 billion in 2021. The following are some of the key highlights of the HNSCC market:
- The market growth is attributed to the established immune checkpoint inhibitors having a high ACOT.
- APAC had the highest share in 2021.
Head and Neck Squamous Cell Carcinomas (HNSCC) Market Outlook, 2021-2031 ($ Billion)
Buy Full Report to Get More Insights into the HNSCC Market Forecast
The HNSCC market research report offers a comprehensive insight into the market through 2031. The report provides an overview of the disease including epidemiology, symptoms, diagnosis, disease management, countries where the disease is prevalent, and leading players associated with the market.
| Market Size (2021) | $1.9 billion |
| Forecast Period | 2021-2031 |
| Key Regions | · APAC
· Europe · The Middle East · North America |
| Leading Players | · SQZ Biotechnologies Co
· MeiraGTx Holdings Plc · Fate Therapeutics Inc · Adaptimmune Therapeutics Plc · Zhejiang Yangshengtang Biotech Co. |
| Enquire & Decide | Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase |
HNSCC Market Insights
Patients may prefer more convenient therapies that do not require IV administration, which will hamper the market growth during the forecast period. However, HNSCC has one of the largest gene therapy and oncolytic virus pipelines with one oncolytic virus, RP-2, which will launch over the forecast period at a lucrative price.
HNSCC Market – Treatment Insights
- HNSCC presents unmet needs that are partially met by cell and gene therapy. Moreover, CGTs have shown promising efficacy data in Phase I/II trials and GlobalData anticipates the launch of 3 CGT agents over the forecast period.
- Checkpoint inhibitors can be used in combination therapies such as Keytruda platinum and fluorouracil for the first-line treatment of metastatic HNSCC.
Buy Full Report to Get More Insights into the HNSCC Market Forecast
HNSCC Market Segmentation by Regions
The key regions in the HNSCC market are APAC, Europe, the Middle East, and North America.
HNSCC Market Analysis by Regions, 2021 (%)
Buy Full Report to Get More Regional Insights on the HNSCC Market
HNSCC Market - Competitive Landscape
A few of the leading players in the HNSCC market are:
- SQZ Biotechnologies Co
- MeiraGTx Holdings Plc
- Fate Therapeutics Inc
- Adaptimmune Therapeutics Plc
- Zhejiang Yangshengtang Biotech Co.
The clinical pipeline for CGTs in HNSCC is dispersed over many different companies, largely consisting of small-medium sized US or China-based biotechs. Some established names such as Replimune, which is a well-known company in the oncolytic virus field have trials that are sponsored by Bristol Myers Squibb.
Scope
The report provides an in-depth analysis of the following:
- Overview of HNSCC including epidemiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
- Topline HNSCC market revenue, annual cost of therapy, and major pipeline product sales in the forecast period.
- Key topics covered include current treatment and pipeline therapies, unmet needs and opportunities, and the drivers and barriers affecting HNSCC therapeutics sales in the 8MM.
- Pipeline analysis: Comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs (Phase II-III).
- Analysis of the current and future market competition in the global HNSCC therapeutics market. Insightful review of the key industry drivers and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
Key Highlights
Report deliverables include a PowerPoint report and Excel-based forecast model
Forecast includes 8 countries
Forecast covers 2021-2031
Seven markets are extrapolated, obtaining a 15-market value for all GBM therapeutics
Reasons to Buy
- Obtain cell & gene therapy sales forecasts across multiple regions
- Gain insight into promising early-stage approaches
Our indication-specific forecast models answer questions such as:
- What is the target patient pool for cell & gene therapies in each cancer indication?
- Which patient groups are more likely to receive these therapies?
- What does the cell & gene therapy clinical-stage pipeline look like in each cancer indication
- What is the anticipated breakdown between autologous and allogeneic cell therapies?
- When will cell & gene therapies launch in each market?
- What is the total market value projected for the forecast end, in 2031?
Table of Contents
Frequently asked questions
-
What was the HNSCC market size in the 15M in 2021?
The total market value for the 15M, which includes both cell and gene therapies and established/traditional HNSCC therapies was $1.9 billion in 2021.
-
Which are the key regions in the HNSCC market?
The key regions in the HNSCC market are APAC, Europe, the Middle East, and North America.
-
Which region had the highest share in the HNSCC market?
APAC had the highest share of the HNSCC market.
-
Who are the leading players in the HNSCC market?
The leading players in the HNSCC market are SQZ Biotechnologies Co, MeiraGTx Holdings Plc, Fate Therapeutics Inc, Adaptimmune Therapeutics Plc, Zhejiang Yangshengtang Biotech Co., Wuhan Binhui Biotechnology Co Ltd, Turnstone Biologics Inc, and Replimune Ltd.
-
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Related reports
View more Head And Neck Cancer reports

